Product Description
Mechanisms of Action: CRTH2 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Brazil | Chile | Colombia | Dominican Republic | Germany | Hungary | India | Ireland | Italy | New Zealand | Russia | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Hypercholesterolemia|Hyperlipoproteinemias|Dyslipidemia|Hyperlipidemia|Type 2 Diabetes|Coronary Artery Disease|Atherosclerosis|Inflammation|Myocardial Ischemia|Oxidative Stress
Phase 3: Dyslipidemia|Hypercholesterolemia|Type 2 Diabetes|Stroke|Hyperlipidemia|Myocardial Infarction|Intermittent Claudication|Peripheral Arterial Disease|Coronary Disease|Coronary Artery Disease|Hyperlipoproteinemias|Lipidoses|Hyperlipoproteinemia Type V|Hyperlipoproteinemia Type II|Myocardial Ischemia|Peripheral Vascular Diseases
Phase 2: Dyslipidemia|Hypercholesterolemia|Rhinitis, Allergic, Seasonal|Asthma|Flushing
Phase 1: Hypercholesterolemia|Hyperlipidemia|Type 2 Diabetes|Dyslipidemia|Hyperlipoproteinemia Type II|Rosacea
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NILACH | P4 |
Terminated |
Atherosclerosis |
2014-07-01 |
|
MK-0524A-119 | N/A |
Terminated |
Hypercholesterolemia|Dyslipidemia |
2013-05-01 |
|
2011-000755-17 | P3 |
Terminated |
Coronary Disease |
2013-03-08 |
|
MK-0524A-133 | P3 |
Terminated |
Hypercholesterolemia|Dyslipidemia |
2013-02-26 |